NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.4301
-0.0088 (-2.01%)
Aug 28, 2026, 12:47 PM EDT - Market open
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
17
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$654,412
Market Cap
15.90M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 0 | - |
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Citius Pharmaceuticals | 23 |
| Lisata Therapeutics | 21 |
| CalciMedica | 16 |
| BioVie | 13 |
| Psyence Biomedical | 12 |
| KALA BIO | 6 |
| Akari Therapeutics, | 6 |
NRSN News
- 15 days ago - NeuroSense Issues CEO Letter to Shareholders - PRNewsWire
- 22 days ago - NeuroSense sees December 2026 as filing date for NDS for PrimeC - TheFly
- 22 days ago - NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada - PRNewsWire
- 4 weeks ago - NeuroSense Therapeutics Registration statement: Registration filing - Filings
- 4 weeks ago - NeuroSense Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - NeuroSense to file NDS to Health Canada for PrimeC for treatment of ALS - TheFly
- 5 weeks ago - NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PRNewsWire
- 7 weeks ago - NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - PRNewsWire